# Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

> **NCT01412957** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 377 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **OTHER:** Best Supportive Care (BSC)
- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT01412957
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2014-06
- **Final completion:** 2016-11
- **Target enrollment:** 377 (ACTUAL)
- **Last updated:** 2017-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01412957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01412957, "Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01412957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*